EP4735116A2 - Anti-trailr2-antigenbindende proteine und verwendungen davon - Google Patents

Anti-trailr2-antigenbindende proteine und verwendungen davon

Info

Publication number
EP4735116A2
EP4735116A2 EP24746100.7A EP24746100A EP4735116A2 EP 4735116 A2 EP4735116 A2 EP 4735116A2 EP 24746100 A EP24746100 A EP 24746100A EP 4735116 A2 EP4735116 A2 EP 4735116A2
Authority
EP
European Patent Office
Prior art keywords
seq
amino acid
acid sequence
cancer
cdr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24746100.7A
Other languages
English (en)
French (fr)
Inventor
Luigi Franchi
Anthony W. Opipari
Elaine Maria PINHEIRO
Robert Thomas ABRAHAM
Laura PREISS
Ferdinand Huber
Paul-Albert KÖNIG
Tamara DAKE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Odyssey Therapeutics Inc
Original Assignee
Odyssey Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Odyssey Therapeutics Inc filed Critical Odyssey Therapeutics Inc
Publication of EP4735116A2 publication Critical patent/EP4735116A2/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP24746100.7A 2023-06-29 2024-06-28 Anti-trailr2-antigenbindende proteine und verwendungen davon Pending EP4735116A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363524095P 2023-06-29 2023-06-29
PCT/US2024/035969 WO2025006846A2 (en) 2023-06-29 2024-06-28 Anti-trailr2 antigen-binding proteins and uses thereof

Publications (1)

Publication Number Publication Date
EP4735116A2 true EP4735116A2 (de) 2026-05-06

Family

ID=91961924

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24746100.7A Pending EP4735116A2 (de) 2023-06-29 2024-06-28 Anti-trailr2-antigenbindende proteine und verwendungen davon

Country Status (9)

Country Link
EP (1) EP4735116A2 (de)
KR (1) KR20260032566A (de)
CN (1) CN121532423A (de)
AR (1) AR133108A1 (de)
AU (1) AU2024308381A1 (de)
IL (1) IL325291A (de)
MX (1) MX2025015221A (de)
TW (1) TW202515917A (de)
WO (1) WO2025006846A2 (de)

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP1400536A1 (de) 1991-06-14 2004-03-24 Genentech Inc. Verfahren zur Herstellung humanisierter Antikörper
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
EP1391213A1 (de) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Zusammensetzungen und Verfahren zur Behandlung von Krebs mit einem Maytansinoid-CD44-Antikörper Immunokonjugat und chemotherapeutische Mittel
WO2004041863A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses therefor
PT1737891E (pt) 2004-04-13 2013-04-16 Hoffmann La Roche Anticorpos anti p-selectina
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
US8188223B2 (en) 2005-05-18 2012-05-29 Ablynx N.V. Serum albumin binding proteins
WO2008020079A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
EP2225277A4 (de) 2007-11-27 2012-03-14 Viventia Biotech Inc Antikörper gegen ein mit krebs assoziiertes epitop der variante nfkbib und anwendungen davon
EP2285833B1 (de) 2008-05-16 2014-12-17 Ablynx N.V. Gegen cxcr4 und andere gpcr gerichtete aminosäuresequenzen sowie verbindungen damit
WO2011003622A1 (en) 2009-07-10 2011-01-13 Ablynx N.V. Method for the production of variable domains
US9120855B2 (en) * 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
KR101860963B1 (ko) 2010-04-23 2018-05-24 제넨테크, 인크. 이종다량체 단백질의 생산
ES2692268T5 (en) 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
SG10201805064SA (en) 2011-06-23 2018-07-30 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2723771B1 (de) 2011-06-23 2019-09-11 Ablynx NV Serumalbumin-bindende proteine
PE20141522A1 (es) 2011-08-17 2014-11-17 Glaxo Group Ltd Proteinas y peptidos modificados
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
EP4707303A2 (de) 2014-05-16 2026-03-11 Ablynx NV Verbesserte variable immunglobulindomänen
AU2015366284B2 (en) 2014-12-19 2021-07-22 Ablynx N.V. Cysteine linked nanobody dimers
JP7001474B2 (ja) 2015-01-21 2022-01-19 インヒブルクス，インコーポレイティド 非免疫原性単一ドメイン抗体
EP3271391A1 (de) 2015-03-20 2018-01-24 Ablynx N.V. Glykosylierte variable immunglobulin-einzeldomänen
CA2991634C (en) * 2015-07-16 2026-03-17 Inhibrx Biosciences, Inc. Multivalent and multispecific dr5-binding fusion proteins
LT3374392T (lt) 2015-11-13 2022-01-25 Ablynx Nv Patobulinti serumo albuminą surišantys imunoglobulino kintami domenai
AU2016357460B2 (en) 2015-11-18 2023-07-27 Ablynx Nv Improved serum albumin binders
RU2022101604A (ru) 2016-12-07 2022-03-29 Аблинкс Нв Улучшенные отдельные вариабельные домены иммуноглобулина, связывающиеся с сывороточным альбумином
IL267897B2 (en) 2017-01-17 2025-02-01 Ablynx Nv Improved serum albumin binders
JP7219220B2 (ja) 2017-01-17 2023-02-07 アブリンクス エン．ヴェー． 改善された血清アルブミン結合剤
US20190100587A1 (en) 2017-10-02 2019-04-04 Covagen Ag IgG1 Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS
WO2020047705A1 (zh) * 2018-09-03 2020-03-12 安菲尼生命科技有限公司 Dr5单域抗体及其用途
GB2595299B (en) 2020-05-21 2022-08-03 Mabsolve Ltd Modified immunoglobulin FC regions

Also Published As

Publication number Publication date
WO2025006846A2 (en) 2025-01-02
WO2025006846A3 (en) 2025-03-06
CN121532423A (zh) 2026-02-13
KR20260032566A (ko) 2026-03-09
AR133108A1 (es) 2025-08-27
TW202515917A (zh) 2025-04-16
AU2024308381A1 (en) 2025-11-20
WO2025006846A8 (en) 2025-05-01
MX2025015221A (es) 2026-02-03
IL325291A (en) 2026-02-01

Similar Documents

Publication Publication Date Title
US10233258B2 (en) Bispecific binding proteins that bind CD40 and mesothelin
JP2023051968A (ja) 多重特異的ＮＫｐ４６結合タンパク質
KR20180033501A (ko) Dll3 및 cd3에 결합하는 이중특이적인 항체 작제물
EP4421093A1 (de) Antigenbindendes protein mit zwei fc-domänen und verwendung davon
US12195543B2 (en) Anti-FLT3 antigen binding proteins
CN119173528A (zh) 针对cd277和肿瘤抗原的双特异性抗体
KR20250040586A (ko) 감마-델타 t 세포 수용체에 결합하는 변이체 항체
WO2024192065A1 (en) Anti-cd25 antigen-binding proteins and uses thereof
EP4648792A2 (de) Anti-tnfr2-antigenbindende proteine und verwendungen davon
EP3623383A1 (de) Verbesserte bispezifische flt3xcd3-antigenbindende proteine
EP4735116A2 (de) Anti-trailr2-antigenbindende proteine und verwendungen davon
WO2025080751A2 (en) Anti-cdh17 antigen-binding proteins and uses thereof
WO2025217240A1 (en) Anti-tnfr2 antigen-binding proteins and uses thereof
WO2026006708A2 (en) Anti-cd25 antigen-binding proteins and uses thereof
WO2026006809A1 (en) Multispecific molecules binding tnfr2 and cd25 and uses thereof
RU2830982C2 (ru) Улучшенные анти-flt3 антигенсвязывающие белки
WO2025255435A2 (en) Antigen-binding proteins against serum albumin and uses thereof
WO2025255558A2 (en) Anti-thymic stromal lymphopoietin (tslp) antigen-binding proteins and uses thereof
KR20240156564A (ko) 두 개의 Fc 도메인을 포함하는 항원 결합 단백질 및 이의 용도
KR20250135302A (ko) 항-cmet 항체 및 사용 방법
CN120917047A (zh) 抗cldn6和抗cd3多特异性抗体及其使用方法
TW202544031A (zh) 抗tigit/抗pd-l1雙特異性抗體及其用途

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE